Carvedilol significantly reduced mortality from cardiovascular causes and Study Rundown: The CAPRICORN trial demonstrated that. London, UK – Results of the CAPRICORN trial confirm the benefit of the beta blocker carvedilol (Coreg® – GlaxoSmithKline) in reducing. Description: The CArvedilol Post-infaRct survIval COntRolled evaluatioN ( CAPRICORN) trial was a randomized, placebo-controlled trial.
|Published (Last):||20 March 2004|
|PDF File Size:||11.4 Mb|
|ePub File Size:||8.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
User Username Password Remember me Not a user? About the Authors B.
CAPRICORN – Wiki Journal Club
The Lopressor Intervention Trial: Effect on mortality of metoprolol in acute myocardial infarction. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. A randomised trial of propranolol in patients with acute myocardial infarction, I: Effects of carvedilol early after myocardial infarction: Keywords myocardial infarction, beta-blocker, carvedilol, metoprolol.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: Center for Drug Evaluation and Research, U.
A placebo-controlled, randomized trial. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. Effect of timing, dosage, and infarct location. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction.
Pharma commercial intelligence, news & analysis | Evaluate
Clopidogrel and metoprolol in myocardial infarction. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol.
This work is licensed under a Creative Commons Attribution 4. Randomised trial of intravenous atenolol among 16 cases of suspected acute myocardial infarction: A double-blind randomized trial. Rational Pharmacotherapy in Cardiology. Basic Clin Pharmacol Toxicol ; 2: These beneficial effects are additional to those of evidence-based treatments for acute myocardial infarction including ACE inhibitors.
Email the author Login required. Study medication was progressively increased to a maximum of 25 mg twice daily during the next weeks, and patients were followed up until the requisite number of primary endpoints had occurred.
METOPROLOL AND CARVEDILOL IN THERAPY OF ACUTE MYOCARDIAL INFARCTION: WHEN AND WHICH DRUG TO PREFER
J Am Coll Cardiol ;49 9: Email this article Login required. Keywords acute coronary syndrome ambulatory blood pressure monitoring amlodipine apixaban arterial hypertension atherosclerosis atrial fibrillation beta-blockers cardiovascular diseases chronic heart failure hypertension ischemic heart disease lisinopril metabolic syndrome myocardial infarction obesity risk factors rivaroxaban statins stroke warfarin.
Body weight changes with beta-blockers use: Generally, the patients recruited to these trials were at low risk: Editor in chief Boytsov S. MoscowRussia Petroverigsky per. We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice.
S Food and Drug Administration.
Data of the studies comparing influence of metoprolol tartrate and carvedilol on MI pathogenesis are presented. Article Tools How to cite item. Clin Res Cardiol ;95 1: Int J Cardiol ;10 3: Eur Heart J ;8 The primary endpoint was all-cause mortality or hospital admission for cardiovascular problems.
Carvedilol protects better against vascular events than metoprolol in heart failure: Eur Heart J ;29 Pacing Clin Electrophysiol ;28 Suppl 1: Clin Res Cardiol ;95 2: Am J Med ; 5: Last changes in guidelines regarding beta-blockers prescription to patients with MI are presented. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: